Display options
Cite
Chung AW, Anand K, Anselme AC, et al. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021;13(624):eabj5070doi: 10.1126/scitranslmed.abj5070.
Chung, A. W., Anand, K., Anselme, A. C., Chan, A. A., Gupta, N., Venta, L. A., Schwartz, M. R., Qian, W., Xu, Y., Zhang, L., Kuhn, J., Patel, T., Rodriguez, A. A., Belcheva, A., Darcourt, J., Ensor, J., Bernicker, E., Pan, P. Y., Chen, S. H., Lee, D. J., Niravath, P. A., & Chang, J. C. (2021). A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Science translational medicine, 13(624), eabj5070. https://doi.org/10.1126/scitranslmed.abj5070
Chung, Andrew W, et al. "A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer." Science translational medicine vol. 13,624 (2021): eabj5070. doi: https://doi.org/10.1126/scitranslmed.abj5070
Chung AW, Anand K, Anselme AC, Chan AA, Gupta N, Venta LA, Schwartz MR, Qian W, Xu Y, Zhang L, Kuhn J, Patel T, Rodriguez AA, Belcheva A, Darcourt J, Ensor J, Bernicker E, Pan PY, Chen SH, Lee DJ, Niravath PA, Chang JC. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med. 2021 Dec 15;13(624):eabj5070. doi: 10.1126/scitranslmed.abj5070. Epub 2021 Dec 15. PMID: 34910551.
Copy Download .nbib Format: NLM
Share it on

Sci Transl Med. 2021 Dec 15;13(624):eabj5070. doi: 10.1126/scitranslmed.abj5070. Epub 2021 Dec 15.

A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.

Science translational medicine

Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta, Luz A Venta, Mary R Schwartz, Wei Qian, Yitian Xu, Licheng Zhang, John Kuhn, Tejal Patel, Angel A Rodriguez, Anna Belcheva, Jorge Darcourt, Joe Ensor, Eric Bernicker, Ping-Ying Pan, Shu Hsia Chen, Delphine J Lee, Polly A Niravath, Jenny C Chang

Affiliations

  1. Texas A&M University Health Science Center, Bryan, TX 77807, USA.
  2. Houston Methodist Research Institute, Houston, TX 77030, USA.
  3. Houston Methodist Cancer Center, Houston, TX 77030, USA.
  4. Lundquist Institute, Torrance, CA 90502, USA.
  5. Department of Radiology, Houston Methodist Hospital, Houston, TX 77030, USA.
  6. Houston Methodist Department of Pathology and Genomic Medicine, Houston, TX 77030, USA.
  7. University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
  8. Department of General Oncology MD Anderson Cancer Center, Houston, TX 77030, USA.
  9. Austin Cancer Center, Austin, TX 78705, USA.
  10. David Geffen School of Medicine at Los Angeles, CA 90095, USA.

PMID: 34910551 DOI: 10.1126/scitranslmed.abj5070

Abstract

[Figure: see text].

Publication Types